BoomRay Pharmaceuticals Closes Nearly RMB 300 Million in Series A Financing

BoomRay Pharmaceuticals is at the forefront of creating next-generation targeted radionuclide-conjugated drugs. HongShan led this round, with participation from Riverhead Capital, Tririver Capital, Puhua Capital, Tsing Song Capital, Life Sciences Investments Fund, and Jinsheng Investment.

CEC Capital Group acted as the exclusive financial advisor for BoomRay Pharmaceuticals in this transaction.

Following this financing, the company will accelerate the clinical development and registration of multiple self-developed pipeline products. It will also expedite the construction of research centers and production facilities, and intensify its global business development partnerships.